Dave Mazza News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Correction territory, the dow has to be down at least 361 points. We are down 766. The nasdaq has to be down 145. We are already down on the nasdaq at this moment by significant 276. And the s p has to lose a minimum of 68 points. S p right now down 87. Goldman sachs now believes that American Companies will see zero Earnings Growth this year if the coronavirus becomes more widespread than it already is. Backing up goldmans call, a slew of companies revealing new warnings about how the deadly outbreak could hurt their businesses. Countdown bringing out all the big guns for this final hour of t...

Nasdaq advanced 0. 02 . Unfortunately its not all earnings weve got to deal with next week. So whats your game plan . Let me show you mine. Ive been saying that the fed is prepping us right now for a december rate hike, a big reason why this market cant get out of its own way and feels so sloppy. More on that later. Now, fed vice chairman Stanley Fischer will speak monday, and hes been a major rate hike proponent. I bet his new speech will cause this market to get hit. Hes hurt stocks virtually every time hes opened his mouth in 2016. But fischers words will inevitably help some stocks, notabl...

Unfortunately its not all earnings weve got to deal with next week. So whats your game plan . Let me show you mine. Ive been saying that the fed is prepping us right now for a december rate hike, a big reason why this market cant get out of its own way and feels so sloppy. More on that later. Now, fed vice chairman Stanley Fischer will speak monday, and hes been a major rate hike proponent. I bet his new speech will cause this market to get hit. Time hes opened his mouth in 2016. But fischers words will inevitably help some stocks, notably the banks, which benefit from higher rates, and bank o...

While Novo Nordisk and Eli Lilly have soared in the past year, Roundhill Investments sees bigger gains ahead for the GLP-1 drugmakers.

While Novo Nordisk and Eli Lilly have soared in the past year, Roundhill Investments sees bigger gains ahead for the GLP-1 drugmakers.